Company intelligence / Profile preview

Yongin Cell Therapy Center

Yongin-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~500
Development stage: Other

Overview

GC Cell is a South Korean biotechnology company formed through the merger of GC LabCell and GC Cell. The company operates the Cell Center in Yongin, which is one of the largest cell therapy manufacturing facilities in Asia. GC Cell specializes in the development of next-generation immune cell therapies, particularly Natural Killer (NK) cell and CAR-NK therapies, while also providing comprehensive cell therapy CDMO services. Their business model integrates R&D, manufacturing, and commercialization of cell-based medicines for oncology and inflammatory indications.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyNK cell therapyCAR-NK cell therapyStem cell therapy
Industry: Biotech

Partnerships

MSDArtiva Biotherapeutics

Beyond the preview

Go deeper on Yongin Cell Therapy Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yongin Cell Therapy Center.

Explore the full profile